HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

FDA shares guide on genome editing best practices

The FDA's guidance emphasises the potential of NGS methods to mitigate safety risks associated with therapies incorporating genome editing.

By Pharmaceutical Technology · Apr 15, 2026 · via Pharmaceutical Technology
FDA shares guide on genome editing best practices

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
policyformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
PolicyFierceBiotech ↗
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
May 25, 2026
Lilly Targets Church-Linked Pharmacies in $200M Trulicity Rebate Fraud Allegation
PolicyBriefing
Lilly Targets Church-Linked Pharmacies in $200M Trulicity Rebate Fraud Allegation
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
May 25, 2026
STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further
PolicySTAT News ↗
STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…
May 22, 2026